BioSpace News Archive

Drug Development

Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting

Puma Biotechnology, Inc. announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma’s investigational drug PB272 (neratinib) given in combination with the antibody drug conjugate T-DM1 (Kadcyla, ado-trastuzumab emtansine) were presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 2, 2018
·
7 min read
Drug Development

Deciphera Pharmaceuticals Reports Updated Interim Phase 1 Clinical Study Results with DCC-2618 at The 2018 American Society of Clinical Oncology Annual Meeting (ASCO) and Provides Additional Clinical and Regulatory Updates on DCC-2618

Deciphera Pharmaceuticals, Inc. announced the presentation today of updated data from its ongoing Phase 1 clinical trial of DCC-2618.

June 2, 2018
·
10 min read
Drug Development

X4 Pharmaceuticals Reports Positive Clinical Data from Phase 2 Expansion Study of X4P-001-IO and Axitinib in Patients with Clear Cell Renal Cell Carcinoma

X4 Pharmaceuticals announced positive clinical results from the Phase 2 expansion of an ongoing Phase 1/2 study of X4P-001-IO in combination with Inlyta® (axitinib) in patients with clear cell renal cell carcinoma (ccRCC).

June 2, 2018
·
4 min read
BioMidwest

NantOmics to Share Results of NantOmics Pharmacogenomics Test at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantOmics, LLC, will present results from the NantOmics pharmacogenomics test, an integrative panomic approach to pharmacogenomics screening, during the developmental therapeutics session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

June 2, 2018
·
2 min read
Drug Development

New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna® remain in remission almost three years after stopping therapy

New Novartis data from two long-term Treatment-free Remission (TFR) studies in patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase (CP) will be presented during the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

June 2, 2018
·
14 min read
BioMidwest

NantOmics to Present Results of DESMOPAZ Study from French Sarcoma Group (FSG) at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantOmics, LLC will present findings on how pazopanib (PZ) has meaningful clinical activity in patients with progressive desmoid tumors (DT) during the sarcoma session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

June 2, 2018
·
2 min read
BioMidwest

NantHealth and NantOmics to Present Data on the Frequency of Non-Expressed Variants Tested by Standard NGS Panel at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

NantHealth, Inc. and NantOmics, LLC will present findings on how 17 percent of next generation sequencing (NGS) 50 gene panel variants are not expressed in RNA sequencing during the tumor biology session at the American Society of Clinical Oncology (ASCO) 2018 Annual Meeting.

June 2, 2018
·
3 min read